Rational drug design of G-quartet DNA as anti-cancer agents

Current Pharmaceutical Design

Volumn 11, Issue 22, 2005, Pages 2841-2854

  Jing, Naijie ^a   Sha, Wei ^a   Li, Yidong ^a   Xiong, Weijun ^a   Tweardy, David J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Breast cancer; Cancer therapy; DNA drugs; Drug delivery; Drug design; G quartet oligodeoxynucleotides (GQ ODN); Prostate cancer; Signal transducer and activator of transcription (STAT) 3

Indexed keywords

ANTINEOPLASTIC AGENT; BSU 1051; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DNA TOPOISOMERASE; GRO 29A; LIPOSOME; MYC PROTEIN; NEW DRUG; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE; PLACEBO; PROTEIN P53; STAT3 PROTEIN; T 30923; T 40212; T 40214; T 40215; T 40216; T 40217; T 40231; UNCLASSIFIED DRUG; ZINTEVIR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; DNA REPLICATION; DNA SEQUENCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; GENETIC TRANSCRIPTION; HUMAN; LD 50; METASTASIS; MULTIPLE DRUG DOSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DNA INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; DRUG DESIGN; HUMANS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 22944438723     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054546761     Document Type: Review

References (88)

1. Cho-Chung YS. DNA drug design for cancer therapy. Curr Pharm Design 2004; (this issue).
2. Coppelli, F. M. and Grandis, J. R. Oligonucleotides as anticancer agents: from the benchside to the clinical and beyond. Curr Pharm Design 2004; (this issue).
3. Sen D, Gilbert W. Formation of parallel four-stranded complexes by guanine-rich motif for meiosis. Nature 1998; 334: 364-6.
4. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 564-6.
5. Marshall WS, Beaton G, Stein CA, Matsukura M, Caruthers MH. Inhibition of HIV activity by phosphodithioate oligonucleoxytidine. Proc Natl Acad Sci USA 1992; 89: 6256-9.
6. Wyatt JR, Vickers TA, Roberson JL, Buckeit RW, Klimkait T, Debaets E, et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of HIV envelope-mediated cell fusion. Proc Natl Acad Sci USA 1994; 91: 1356-60.
7. Rando RF, Ojwang J, Elbaggari A, Reyes GR, Tinder R, McGrath MS, et al. Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. J Biol Chem 1995; 270: 1754-60.
8. Mazumder A, Neamati N, Ojwang JO, Sunder S, Rando RF, Pommier Y. Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 1996; 35: 13762-71.
9. Jing N, Rando FR, Pommier Y, Hogan ME. Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. Biochemistry 1997; 36: 12498-505.
10. Henderson E. Telomere DNA structure. Telomeres, Cold Spring Harbor Laboratory Press 1995; 11-34.
11. Gellert M, Lipsett MN, Davies DR. Helix formation by guanylic acid. Proc Natl Acad Sci USA1962; 48: 2013-18.
12. Sundquist WI, Klug A. Telomeric DNA dimerizes by formation of guanine tetrads between hairpin loops. Nature 1989; 342: 825-8.
13. Smith FW, Feigon J. Quadruplex structure of Oxytricha telomeric DNA oligonucleotides. Nature 1992; 356: 164-8.
14. Kang CH, Zhang X, Ratliff R, Moyzis R, Rich A. Crystal structure of four-stranded Oxytricha telomeric DNA. Nature 1992; 356: 126-31.
15. Fry M, Leob LA. The fragile X syndrome d(CGG)n nucleotide repeats form a stable tetrahelical structure. Proc Natl Acad Sci USA 1994; 91: 4950-4.
16. Sundquist WI, Heaphy S. Evidence for interstrand quadruplex formation in the dimerization of human immunodeficiency virus 1 genomic RNA. Proc Natl Acad Sci USA 1993; 90: 3393-7.
17. Awang G, Sen D. Mode of dimerization of HIV-1 genomic RNA. Biochemistry 1993; 32: 11453-7.
18. Sen D, Gilbert W. Formation of parallel four-stranded complexes by guanine-rich motif for meiosis. Nature 1998; 334: 364-6.
19. Williamson JR. G-quartet structures in telomeric DNA. Annu Rev Biophys Biomol Struct 1994; 23: 703-30.
20. Gilber DE, Feigon J. Multistranded DNA structures. Curr Opin Struct Biol 1999; 9: 305-14.
21. Rhodes R, Giraldo R. Telomere structure and function. Curr Opin Struct Biol 1995; 5: 311-22.
22. Shafer RH, Smirnov I. Biological aspects of DNA/RNA quadruplexes. Bioplolymers 2001; 56: 209-27.
23. Sen D, Gillbert W. A sodium-potassium switch in the formation of four-stranded G4-DNA. Nature 1990: 344: 410-4.
24. Jing N, De Clercq E, Rando FR, Pallansch L, Lackman-Smith C, Lee S, et al. Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. J Biol Chem 2000; 275: 3421-30.
25. Pilch DS, Plum GE, Breslauer KJ. The thermodynamics of DNA structures that contain lesions or guanine tetrads. Curr Opin Struct Biol 1995; 5: 334-42.
26. Mergny JL, Phan AT, Lacroix L. Following G-quartet formation by UV-spectroscopy. FEBS Lett 1998; 435: 74-8.
27. Gou Q, Lu M, Kallenbach NR. Effect of thymine tract length on the structure and stability of model telomeric sequences. Biochemistry 1993; 32: 3596-603.
28. Han H, Hurley LH. G-quadruplex DNA: a potential target for anticancer drug design. Trends Pharmacol Sci 2000; 21: 136-42.
29. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1995; 268: 1115-7.
30. Mata JE, Joshi SS, Palen B, Pirruccello SJ, Jackson JD, Elias N, et al. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol Appl Pharmacol 1997; 144: 189-97.
31. Raymond E, Soria JC, Izbicka E, Boussin F, Hurley L, Von Hoff DD. DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. Invest New Drugs 2000; 18: 123-37.
32. Sun D, Lopez-Guajardo CC, Quada J, Hurley LH, Von Hoff DD. Regulation of catalytic activity and processivity of human telomerase. Biochemistry 1999; 38: 4037-44.
33. Yu H, Jove R. The STATS of cancer-new molecular targets come of age. Nature Review/Cancer 2004; 4: 97-105.
34. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998; 16: 3323-30.
35. Perry PJ, Reszka AP, Wood AA, Read MA, Gowan SM, Dosanjh HS, et al. Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones. J Med Chem 1998; 41: 4873-84.
36. Perry PJ, Gowan SM, Reszka AP, Polucci P, Jenkins TC, Kelland LR, et al. 1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. J Med Chem 1998; 41: 3253-60.
37. Izbicka E, Wheelhouse RT, Raymond E, Davidson KK, Lawrence RA, Sun D, et al. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res 1999; 59: 639-44.
38. Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY, et al. G-quadruplexes as targets for drug design. Pharmacol Ther 2000; 85: 141-58.
39. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991; 56: 1-48.
40. Marcu KB, Bossone SA, Patel AJ. myc function and regulation. Annu Rev Biochem 1992; 61: 809-60.
41. Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998; 12: 633-51.
42. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci USA 2002; 99: 11593-8.
43. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci USA 1996; 93: 4827-32.
44. Saretzki G, Sitte N, Merkel U, Wurm RE, von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene 1999; 18: 5148-58.
45. Wang, JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-40.
46. Arimondo, PB, Riou J-F, Mergy J-L, Tazi J, Sun J-S, Garestier T, et al. Interaction of human DNA topoisomerase I with G-quartet structures. Nucleic Acids Res 2000; 28: 4832-8.
47. Jing N, Marchand C, Liu J, Mitra R, Hogan ME, Pommier Y. Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in vitro. J Biol Chem 2000; 275: 21460-7.
48. Marchand C, Pourquier P, Laco GS, Jing N, Pommier Y. Interaction of human topoisomerase I with Guanosine quartet-forming and Guanosine-rich single-stranded DNA and RNA oligonucleotides. J Biol Chem 2002; 277: 8906-11.
49. Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999; 274: 26369-77.
50. Xu X, Hamhouyia F, Thomas SD, Burker TJ, Girvan AC, Glenn McGregor W, et al. Inhibition of DNA replication and induction of Sphase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 2001; 276: 43221-30.
51. Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 2002; 41: 3676-85.
52. Dapic V, Abdomerovic V, Marrington R, Peberdy J, Rodger A, Trent JO, et al. Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res 2003; 31: 2097-107.
53. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659-66.
54. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activatior of transcription 3 and phospho-state 3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003; 9: 594-600.
55. Nagpal JK, Mishra R, Das BR. Activation of Stat3 as one of early events in tobacco chewing-mediated oral carcinogenesis. Am Can Soc 2002; 94: 2393-400.
56. Hsiao J-R, Jin Y-T, Tsai T, Shiau A-L, Wu C-L, Su W-C. Constitutive activation of Stat3 and Stat5 is present in majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 2003; 89: 344-9.
57. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-88.
58. Bromber JF. Activation of STAT proteins and growth control. BioEssay 2001; 23: 161-9.
59. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumor provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-54.
60. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
61. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89: 630-43.
62. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227-32.
63. Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, et al. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Therapeut 2002; 1: 893-9.
64. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (Cucurbitacin I), a selective janus kinase/signal transducer and activitor of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-9.
65. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Design 2004; (this issue).
66. Jing N, Li Y, Xu X, Li P, Feng L, Tweardy D. Targeting Stat3 with G-quartet oligonucleotides in human cancer cells. DNA Cell Biol 2003; 22: 685-96.
67. Becker S, Groner B, Muller C. Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 1998; 394: 145-50.
68. Jing N, Hogan ME. Structure-activity of tetrad-forming oligonucleotides as a potent anti-Hiv therapeutic drug. J Biol Chem 1998; 273: 34992-9.
69. Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of Stat3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004; 64: 6603-6609.
70. Jing N, Marchand C, Liu J, Mitra R, Hogan ME, Pommier Y. Mechanism of Inhibition of HIV-1 Integrase by G-tetrad Forming Oligonucleotides in vitro. J Biol Chem 2000; 275(28): 21460-7.
71. Jing N, Xiong W, Guan Y, Pallansch L, Wang S. Potassium dependent folding: a key to intracellular delivery of G-quartet oligonucleotides as HIV inhibitors. Biochemistry 2002; 41(17): 5397-403.
72. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Kuriyan J. Crystal structure of a tyrosine phosphorylated Stat-1 dimer bound to DNA. Cell 1998; 93: 827-39.
73. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109 Suppl: S121-31.
74. Maurer N, Mori A, Palmer L, Monck MA, Mok KWC, Mui B, et al. Lipid-based systems for the intracellular delivery of genetic drugs. Mol Membrane Biol 1999; 16: 129-40.
75. Chesnoy S, Huang L. Structure and function of lipid-DNA complexes for gene delivery. Annu Rev Biophys Biomol Struct 2000; 29: 27-47.
76. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
77. L is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 1994; 120: 3033-42.
78. L: a little bit to this and a little bit to STAT. Curr Opin Oncol 2001; 12: 543-49.
79. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89: 630-43.
80. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC. Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 1997; 94: 5113-8.
81. Minn AJ, Velez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, et al. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997; 385: 353-7.
82. Bishop JS, Guy-Caffey JK, Ojwang JO, Smith SR, Hogan ME, Cossum PA, et al. G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J Biol Chem 1996; 271: 5698-703.
83. Wallace TL, Gamba-Vitalo C, Loveday KS, Cossum PA. Acute, multipe-dose, and genetic toxicology of AR177, an anti-HIV oligonucleotide. Toxicol Sci 2000; 53: 63-70.
84. Gulley J, Dahut W. Novel clinical trials in androgen-independent prostate cancer. Clin Prostate Cancer 2002; 1: 51-7.
85. Benimetskaya L, Stein CA. Antisense therapy: recent advances and relevance to prostate cancer. Clin Prostate Cancer 2002; 1: 20-30.
86. Ast G. Drug-targeting strategies for prostate cancer. Curr Pharm Design 2003; 9(6): 455-66.
87. Pfitzner E, Kliem S, Baus D, Litterst CM. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Design 2004; 10(23): 2839-50.
88. Tietze LF, Feuerstein T. Enzyme and proton-activated prodrugs for a selective cancer therapy. Curr Pharm Design 2003; 9(26): 2155-75.